減肥藥和給藥平台的成長機會

基於 GLP-1 的藥物以及注射劑和奈米材料傳輸平台將推動產業轉型

新興國家可支配收入的增加促進世界各地久坐的生活方式。送餐應用程式的出現也增加了人們獲取各種美食的機會。這些因素是導致肥胖和其他文明病的主要原因。

身體質量指數（BMI）為 30（或 27 kg/m2）或更高的人被歸類為肥胖，無論是否有合併症。眾所周知，肥胖還會增加多種疾病的風險，包括第2 型糖尿病、癌症死亡率、全因死亡率和心血管疾病。它還會惡化多種疾病和其他相關合併症的預後。

健康的飲食和積極的生活方式對於維持最佳體重指數非常重要。營養補充，食品膳食纖維、維生素、礦物質和益生菌也有助於控制體重。此外，醫療保健專業人員探索肥胖管理的行為介入措施。減重手術是肥胖治療的黃金標準。然而，最近治療方法的進展使得口服和注射藥物減重成為可能。以 GLP-1 為基礎的減肥藥正迅速成為肥胖治療的有力選擇，且具有良好的安全性。

在這項研究中，Frost & Sullivan 分析了新核准的減肥藥的研發管線以及藥物輸送技術的相關進展。它還提供了有關資金籌措、減肥藥和藥物輸送平台共同開發的狀況、肥胖管理實驗狀況以及有前途的抗肥胖候選藥物的作用機制的見解。

目錄

戰略問題

• 為什麼成長越來越困難？策略要務 8（TM）：阻礙成長的因素
• The Strategic Imperative 8（TM）
• 關鍵策略要務對肥胖產業的影響
• 成長機會推動Growth Pipeline Engine（TM）
• 調查方法

成長機會分析

• 非傳染性疾病（NCD）概述
• 範圍
• 區隔
• 生長促進因子
• 成長抑制因素

肥胖藥物管線分析

• 核准的減肥藥概述
• 肥胖治療的遊戲規則改變者
• 應對重磅減肥藥的挑戰
• 肥胖症臨床試驗形勢概述
• 肥胖藥物管線分析
• 抗肥胖藥物的監管狀況：美國和歐洲
• 主要基於 GLP 的雙受體促效劑
• 領先的 GLP 為基礎的肥胖藥物進行第2 期和第3 期臨床試驗
• 新型非 GLP減肥藥概述

藥物輸送創新

• 藥物輸送創新概述
• 給藥創新的特點
• 新藥物輸送創新概況：注射器平台
• 新藥物輸送創新概覽：奈米材料平台

減肥藥和交付平台：收購、合作和資金籌措

• 被大型製藥企業收購
• 與製藥公司的合作
• 肥胖藥物輸送資金籌措狀況概述
• 肥胖藥物傳遞合作夥伴關係概述

肥胖前景

• 肥胖治療的多方面方法
• 減肥藥物輸送平台的未來

成長機會宇宙

• 成長機會1：基於GLP-1的多重促效劑
• 成長機會2：個人化治療策略
• 成長機會3：無針給藥技術的利用

下一步

GLP-1-based Drugs, Along With Injector and Nanomaterial Delivery Platforms, Drive Transformational Industry Growth

The increasing disposable incomes in developing countries have contributed to a sedentary lifestyle worldwide. The advent of food delivery apps has also increased accessibility to various culinary delights. These factors have contributed mainly to obesity and other lifestyle diseases.

People with a body mass index (BMI) of more than or equal to 30 (or 27kg/m2) are classified as obese and may or may not have co-morbidities. Obesity is also known to increase the risk of several diseases, such as type 2 diabetes, cancer mortality, overall mortality, and cardiovascular disorders. It also worsens the prognosis of several diseases and other related co-morbidities.

An active lifestyle with healthy eating practices is crucial for maintaining optimal BMI. Dietary supplementation with fibers, vitamins, minerals, probiotics, and other nutrients can also help manage weight. In addition, healthcare professionals are exploring behavioral interventions for obesity management. Bariatric surgery is the gold standard for obesity treatment. However, recent therapeutic advancement has enabled the launch of oral and injectable drugs for weight loss. GLP-1-based obesity treatments are fast emerging as potent treatment options for obesity and have a favorable safety profile.

In this study, Frost & Sullivan analyzes the emerging and recently approved obesity treatment pipelines and associated advances in drug delivery technologies. We also provide insights into funding, the collaborative landscape of obesity treatments and delivery platforms, the clinical trial landscape for obesity management, and the mechanism of action of promising anti-obesity drug candidates.

Table of Contents

Strategic Imperatives

• Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Obesity Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™
• Research Methodology

Growth Opportunity Analysis

• Overview of Noncommunicable Diseases (NCDs)
• Scope
• Segmentation
• Growth Drivers
• Growth Restraints

Obesity Drugs: Pipeline Analysis

• Overview of Approved Obesity Drugs
• Game Changers for Obesity Management
• Addressing the Challenges of Blockbuster Obesity Drugs
• Overview of the Obesity Clinical Trial Landscape
• Pipeline Analysis of Obesity Drugs
• Regulatory Landscape Overview for Anti-Obesity Drugs: The United States and Europe
• Major Emerging GLP-based Dual Receptor Agonists
• Major Emerging GLP-based Obesity Drugs in Phase 2 and 3 Clinical Trials
• Snapshot of Emerging Non-GLP Obesity Drugs

Drug Delivery Innovations

• Overview of Drug Delivery Innovations
• Features of Drug Delivery Innovations
• Snapshot of Emerging Drug Delivery Innovations: Injector Platforms
• Snapshot of Emerging Drug Delivery Innovations: Nanomaterial Platforms

Obesity Drugs and Delivery Platforms: Acquisitions, Partnerships, and Funding

• Acquisitions by Large Pharma Companies
• Pharma Collaborations
• Overview of the Funding Landscape for Obesity Drug Delivery
• Snapshot of the Partnership Landscape for Obesity Drug Delivery

Obesity Outlook

• A Multipronged Approach to Obesity Management
• The Future of Drug Delivery Platforms for Obesity Management

Growth Opportunity Universe

• Growth Opportunity 1: GLP-1-based Multi-agonists
• Growth Opportunity 2: Individualized Treatment Strategy
• Growth Opportunity 3: The Use of Needle-free Drug Delivery Technologies

Next Steps

• Your Next Steps
• Why Frost, Why Now?
• Legal Disclaimer